Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

KalVista Pharmaceuticals (KALV) Short-term Investments: 2019-2024

Historic Short-term Investments for KalVista Pharmaceuticals (KALV) over the last 3 years, with Dec 2024 value amounting to $86.0 million.

  • KalVista Pharmaceuticals' Short-term Investments was N/A to $86.0 million in Q4 2024 from the same period last year, while for Dec 2024 it was $86.0 million, marking a year-over-year change of. This contributed to the annual value of $178.6 million for FY2024, which is N/A change from last year.
  • As of Q4 2024, KalVista Pharmaceuticals' Short-term Investments stood at $86.0 million, which was down 8.68% from $94.2 million recorded in Q4 2024.
  • KalVista Pharmaceuticals' 5-year Short-term Investments high stood at $178.6 million for Q2 2024, and its period low was $32.6 million during Q1 2021.
  • For the 2-year period, KalVista Pharmaceuticals' Short-term Investments averaged around $96.2 million, with its median value being $86.0 million (2024).
  • Its Short-term Investments has fluctuated over the past 5 years, first crashed by 47.41% in 2021, then surged by 106.99% in 2024.
  • Quarterly analysis of 4 years shows KalVista Pharmaceuticals' Short-term Investments stood at $39.7 million in 2020, then tumbled by 47.41% to $32.6 million in 2021, then reached $45.5 million in 2023, then soared by 106.99% to $86.0 million in 2024.
  • Its last three reported values are $86.0 million in Q4 2024, $94.2 million for Q4 2024, and $142.4 million during Q3 2024.